NY-WEBBING
Webbing , a global MVNO (Mobile Virtual Network Operator) connectivity provider for enterprise mobility and IoT, today announced the immediate availability of WebbingCTRL , a fast and simple global-ready connectivity solution. WebbingCTRL is the only SIM in the world that can easily and remotely become any wireless carrier’s SIM, eliminating network provider lock-in and providing complete control over connectivity with zero-touch provisioning.
IoT connectivity can require substantial costs and time to orchestrate the implementation of network providers. Additionally, IoT use cases are rapidly changing, so organizations need a way to make future-proof decisions today in order to handle connectivity challenges on the horizon. Using the WebbingCTRL platform, organizations can easily add, remove, and swap the carrier for any number of IoT or enterprise deployments to another wireless carrier of their choice with which they have an eSIM subscription. There’s no need for carrier integration.
The IoT environment is accelerating, and connectivity solutions need to adapt to fast-moving deployments now and in the future. The WebbingCTRL eSIM delivers total flexibility to ensure devices have reliable connectivity, anywhere in the world. The ability to remotely provision devices without extra carrier integration or collaboration also vastly reduces time-consuming deployment cycles and could have a huge impact on the ability to scale.
The WebbingCTRL solution eSIM is device agnostic and comes in any form factor. As a result, businesses can gain complete control over connectivity for a wide array of use cases, including:
- Enterprise employee mobile connectivity: Enables organizations to provide seamless connectivity for employees as they cross national boundaries and enter areas where one carrier may have better coverage than another.
- Transportation and logistics : Enable IoT tracking devices to switch automatically from a private network in a warehouse to a public network when in transit.
- Mission-critical IoT: Prevent interruption to operations that depend on connectivity when one carrier’s coverage is down by switching automatically to another.
- Automotive: Connected vehicles need constant connectivity and they cannot always use a roaming carrier due to regional connectivity regulations. WebbingCTRL can automatically change carriers as vehicles cross into new coverage areas or national borders.
“With WebbingCTRL, companies can finally take complete control of their connectivity to ensure business continuity, take advantage of better pricing and coverage and avoid having to physically touch hundreds, even thousands of devices to change carriers,” said Noam Lando, co-founder and CEO at Webbing. “Companies can securely control all their devices’ connectivity, with the confidence to connect anywhere in the world, 24-7, both now and in the future.”
Because WebbingCTRL works independently of SM-DP and SM-SR infrastructure, the carrier change takes place almost immediately, and the eSIM will act just as if the SIM card had been physically changed to the new carrier. And WebbingCTRL is not limited to public networks but can also be used to manage connectivity to private networks.
Additionally, companies can set up business rules that will automatically change the carrier under specific conditions, such as location, country, loss of connectivity or even after a certain amount of time.
For more information about WebbingCTRL and ways to streamline your IoT deployment, contact sales@iamwebbing.com .
About Webbing
Webbing is a global data MVNO that delivers innovative enterprise grade, global connectivity and IoT services. Our secured network of 600+ mobile carriers across more than 200 countries, ensures superior data connectivity between businesses, people, and things wherever the device is located.
Since our foundation in 2010, we have been developing revolutionary SIM technology, powerful management platforms and a robust global network that revolutionize your data, making it relevant and actionable. Our leading-edge solutions deliver a streamlined, centralized, and scalable means of deploying and managing organizations' global fleet of devices. Our experts assist in every step of the device on boarding process to ensure you are set up to meet your organization’s connectivity needs. For more information, visit https://www.webbingsolutions.com/ .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220405005430/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.7.1.2026 11:07:00 CET | Press release
Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January. Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use. Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity. Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on venom immunotherapy,
ARIS Announces New CEO to Lead Agentic AI-led Strategy7.1.2026 10:00:00 CET | Press release
CEO Appointment ARIS, a global leader in process intelligence and transformation software, today announced the appointment of Guillaume Bacuvier as Chief Executive Officer. Guillaume will lead ARIS through its next phase of growth as a fully standalone company, accelerating its evolution from a market leader in Process Intelligence into a foundational platform for enterprises deploying and governing Agentic AI. Guillaume brings deep international leadership experience across technology, data, and software-enabled businesses, with a proven track record of scaling global platforms and leading complex organisations. After starting as a strategic consultant at Booz Allen Hamilton, Guillaume spent over a decade at Google, rising to Vice President in EMEA where he built and scaled some of Google’s largest data-driven businesses in Europe and held P&L responsibility across multiple countries. In the last decade, Guillaume has served as CEO of multi-continent, data-centric companies including
I Squared Capital Acquires Ramudden Global, a Leader in Traffic Management and Infrastructure Safety7.1.2026 09:00:00 CET | Press release
Acquisition will accelerate Ramudden’s ambitious growth plan across North America and Europe supported by strong infrastructure spending tailwinds I Squared Capital, a leading global infrastructure investment manager, today announced that, through its flagship fund, it has agreed to acquire Ramudden Global, from funds advised by Triton Partners (“Triton”), a leading European mid-market sector-specialist investor. Ramudden Global is a leading international provider of traffic management and infrastructure safety services supporting the maintenance and upgrade of essential transport and utility networks. The company operates more than 190 depots across 13 countries in Europe and North America delivering mission-critical services that help to ensure safety, regulatory compliance and continuity of service across road, utility and broader infrastructure works. This investment underscores I Squared Capital’s commitment to investing in essential, regulated, infrastructure businesses that unde
RoslinCT and BOOST Pharma Announce Strategic Manufacturing Agreement to Advance Cell Therapy for Infants with Osteogenesis Imperfecta7.1.2026 09:00:00 CET | Press release
RoslinCT, a global contract development and manufacturing organization (CDMO) specializing in advanced cell therapies, and BOOST Pharma, a clinical-stage biotechnology company developing first-in-class cell therapies for rare paediatric skeletal diseases, today announced a strategic manufacturing partnership to support the development of BOOST Pharma’s cell therapy, BT-101, for the treatment of infants with Osteogenesis Imperfecta (OI), also known as brittle bone disease. Under the service agreement, BOOST Pharma has transferred its manufacturing process to RoslinCT’s state-of-the-art facilities in Edinburgh, Scotland. The partnership will progress toward GMP manufacturing of starting materials and clinical drug product, supporting Phase III clinical development of BT-101. The therapy is an allogeneic mesenchymal stem cell (MSC) product designed to address the underlying cause of OI at the earliest stages of life. BOOST Pharma was founded on pioneering science originating from Karolins
Daiichi Sankyo and GENESIS Pharma Enter Exclusive Agreement for VANFLYTA® Commercialization in Central and Eastern Europe7.1.2026 08:30:00 CET | Press release
Exclusive agreement covers 13 Central and Eastern European markets Collaboration will help expand access to VANFLYTA for patients with newly diagnosed FLT3-ITD positive AML Daiichi Sankyo (TSE: 4568) and GENESIS Pharma have entered into an exclusive license and supply agreement for the distribution and commercialization of VANFLYTA® (quizartinib) in 13 markets across Central and Eastern Europe for the treatment of adult patients with newly diagnosed FLT3-ITD positive acute myeloid leukemia (AML). Under the terms of the agreement, Daiichi Sankyo will be responsible for the manufacturing and supply of VANFLYTA while GENESIS Pharma will lead medical affairs, market access and commercialization efforts in Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Malta, Poland, Romania, Slovakia and Slovenia. Financial terms of the agreement are not being disclosed. VANFLYTA was approved in the EU in November 2023 for the treatment of adult patients with newly diagnose
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
